Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel β-catenin/TCF target gene

Cancer Research

Volumn 68, Issue 11, 2008, Pages 4277-4286

  Ganesan, Kumaresan ^a   Ivanova, Tatiana ^a   Wu, Yonghui ^a   Rajasegaran, Vikneswari ^b   Wu, Jeanie ^a   Ming, Hui Lee ^a   Yu, Kun ^a   Sun, Young Rha ^d   Hyun, Cheol Chung ^d   Ylstra, Bauke ^e   Meijer, Gerrit ^e   Kon, Oi Lian ^a   Grabsch, Heike ^f   Tan, Patrick ^a,b,c  

^a National Cancer Center

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d Yonsei University College of Medicine   (South Korea)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALVASCULIN; PHOSPHOLIPASE A2; T CELL FACTOR PROTEIN; WNT PROTEIN; PHOSPHOLIPASE A2 GROUP II; PLA2G2A PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CELL MIGRATION; COLON CANCER; EPIGENETICS; GENE ACTIVITY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; METHYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE;

BASE SEQUENCE; BETA CATENIN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION PROFILING; GROUP II PHOSPHOLIPASES A2; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TCF TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 49249097447     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6517     Document Type: Article

References (40)

1. Human cancers by organ site, Stomach Cancer. In: Stewart BW KP, editor. World cancer report-World Health Organization. Lyon: IARC Press; 2003. p. 194-7.
2. Sun W, Haller DG. Recent advances in the treatment of gastric cancer. Drugs 2001;61:1545-51.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
4. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42.
5. Leung SY, Chen X, Chu KM, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 2002;99:16203-8.
6. Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 2002;68-69:3-58.
7. Belinsky GS, Rajan TV, Saria EA, Giardina C, Rosenberg DW. Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog 2007;46:106-16.
8. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997;17:88-91.
9. Graff JR, Konicek BW, Deddens JA, et al. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 2001;7:3857-61.
10. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 1995;81:957-66.
11. Aggarwal A, Guo DL, Hoshida Y, et al. Topological and functional discovery in a gene coexpression meta-network of gastric cancer. Cancer Res 2006;66:232-41.
12. Nojima M, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007;26:4699-713.
13. Caca K, Kolligs FT, Ji X, et al. β- and γ-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 1999;10:369-76.
14. Suriano G, Vrcelj N, Senz J, et al. β-catenin (CTNNB1) gene amplification: a new mechanism of protein overexpression in cancer. Genes Chromosomes Cancer 2005;42:238-46.
15. Niida A, Hiroko T, Kasai M, et al. DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene 2004;23:8520-6.
16. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-7.
17. Yochum GS, McWeeney S, Rajaraman V, Cleland R, Peters S, Goodman RH. Serial analysis of chromatin occupancy identifies β-catenin target genes in colorectal carcinoma cells. Proc Natl Acad Sci U S A 2007;104:3324-9.
18. Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
19. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100A4, a mediator of metastasis. J Biol Chem 2006;281:677-80.
20. Kim M, Gans JD, Nogueira C, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81.
21. Jiang J, Neubauer BL, Graff JR, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002;160:667-71.
22. Kennedy BP, Soravia C, Moffat J, et al. Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 1998;58:500-3.
23. Chesire DR, Isaacs WB. β-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer 2003;10:537-60.
24. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-80.
25. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
26. Zou B, Chim CS, Zeng H, et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology 2006;131:1835-43.
27. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q. Pharmacologic modulation of glycogen synthase kinase-3β promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 2005;65:9012-20.
28. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175-86.
29. Haluska FG, Thiele C, Goldstein A, Tsao H, Benoit EP, Housman D. Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines. Int J Cancer 1997;72:337-9.
30. Praml C, Amler LC, Dihlmann S, Finke LH, Schlag P, Schwab M. Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa. Oncogene 1998;17:2009-12.
31. Wendum D, Svrcek M, Rigau V, et al. cyclooxygenase (COX)-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod Pathol 2003;16:130-6.
32. Cho YG, Nam SW , Kim TY, et al. Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer. APMIS 2003;111:539-45.
33. El-Rifai W, Frierson HF, Jr., Harper JC, Powell SM, Knuutila S. Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 2001;92:832-8.
34. Yonemura Y, Endou Y, Kimura K, et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000;6:4234-42.
35. Yu GZ, Wang JJ, Chen Y, Ni CR, Zhu MH. [Expressions of nm23, P53 and S100A4 proteins and their relationships with metastasis potential in gastric carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi 2006;9:165-9.
36. O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res 2007;67:8975-9.
37. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-10.
38. Kim B, Koo H, Yang S, et al. TC1(C8orf4) correlates with Wnt/β-catenin target genes and aggressive biological behavior in gastric cancer. Clin Cancer Res 2006;12:3541-8.
39. Burbano RR, Assumpcao PP, Leal MF, et al. C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res 2006;26:2909-14.
40. Onoda N, Maeda K, Chung YS, et al. Overexpression of c-myc messenger RNA in primary and metastatic lesions of carcinoma of the stomach. J Am Coll Surg 1996;182:55-9.